Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
STRIKE trial: what clinicians have said so far
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- NCT06661720 ↗
- Recruiting
- Alliance for Clinical Trials in Oncology
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on STRIKE yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on STRIKE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma (RCC); Stage II Renal Pelvis Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8
- Interventions
- Pembrolizumab; Tivozanib; Biospecimen Collection; MRI; Computed Tomography; Biopsy; Questionnaire Administration
- Arms
- Arm 1 (Pembrolizumab) · Active comparator
- Arm 2 (pembrolizumab + tivozanib) · Experimental
- Enrollment
- 1,040 (estimated)
- Primary outcomes
- Disease-free survival (DFS)
- Sponsor
- Alliance for Clinical Trials in Oncology
- Start
- Mar 14, 2025
- Primary completion
- Nov 2037 (estimated)
- Results posted
- No
- Registry record
- NCT06661720 · updated Nov 3, 2026